Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress

Asano,Takako; Sato,Akinori; Isono,Makoto; Okubo,Kazuki; Ito,Keiichi; Asano,Tomohiko

doi:10.3892/br.2015.523

Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress

Authors:
- Takako Asano
- Akinori Sato
- Makoto Isono
- Kazuki Okubo
- Keiichi Ito
- Tomohiko Asano
View Affiliations

Affiliations: Department of Urology, National Defense Medical College, Tokorozawa, Saitama 359‑8513, Japan
Published online on: September 29, 2015 https://doi.org/10.3892/br.2015.523
Pages: 797-801

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is no curative treatment for advanced renal cancer, and a novel treatment approach is urgently required. Inducing ubiquitinated protein accumulation and endoplasmic reticulum (ER) stress has recently emerged as a new approach in the treatment of malignancies. In the present study, we hypothesized that the histone deacetylase inhibitor belinostat would increase the amount of unfolded proteins in cells by inhibiting heat‑shock protein (HSP) 90, and that the proteasome inhibitor bortezomib would inhibit their degradation by inhibiting the proteasome, thus causing ubiquitinated protein accumulation and ER stress synergistically. The combination of bortezomib and belinostat induced significant increases in apoptosis and inhibited renal cancer growth synergistically (combination indexes <1). The combination also suppressed colony formation significantly (P<0.05). As co‑treatment with the pan‑caspase inhibitor Z‑VAD‑FMK changed the number of Annexin V‑positive cells, this combination‑induced apoptosis was considered caspase dependent. Mechanistically, the combination synergistically caused ubiquitinated proteins to accumulate and induced ER stress, as evidenced by the increased expression of glucose‑regulated protein 78 and HSP70. To the best of our knowledge, this is the first study demonstrating the beneficial combined effect of bortezomib and belinostat in renal cancer cells. The study provides a basis for clinical studies with the combination in patients with advanced renal cancer.

View Figures

View References

1	Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al: TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
2	Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 295:2516–2524. 2006. View Article : Google Scholar : PubMed/NCBI
3	Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al: RECORD-1 Study Group: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
4	Liu Y and Ye Y: Proteostasis regulation at the endoplasmic reticulum: A new perturbation site for targeted cancer therapy. Cell Res. 21:867–883. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 280:26729–26734. 2005. View Article : Google Scholar : PubMed/NCBI
6	Naujokat C and Hoffmann S: Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest. 82:965–980. 2002. View Article : Google Scholar : PubMed/NCBI
7	Sato A and Asano T, Ito K, Sumitomo M and Asano T: Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int. 109:1258–1268. 2012. View Article : Google Scholar : PubMed/NCBI
8	Sato A and Asano T, Isono M, Ito K and Asano T: Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells. BMC Urol. 14:712014. View Article : Google Scholar : PubMed/NCBI
9	Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, et al: Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: A multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol. 30:3361–3367. 2012. View Article : Google Scholar : PubMed/NCBI
10	Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P, Wang L, Mason J, Pham PA, Tsao MS, et al: Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 46:1573–1579. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I and Gandara D: Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 4:97–101. 2009. View Article : Google Scholar : PubMed/NCBI
12	Giaccone G, Rajan A, Berman A, Kelly RJ, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, et al: Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol. 29:2052–2059. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, LaPlant B, Laumann K, Erlichman C and DiPersio J: Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol. 91:33–38. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE and Buhl-Jensen P: A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 81:170–176. 2008. View Article : Google Scholar : PubMed/NCBI
15	Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE and O'Connor OA: Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 16:554–565. 2010. View Article : Google Scholar : PubMed/NCBI
16	Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ and Eckhardt SG: Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 31:1093–1103. 2011.PubMed/NCBI
17	Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P and Grant S: Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol. 153:222–235. 2011. View Article : Google Scholar : PubMed/NCBI
18	Feng R, Oton A, Mapara MY, Anderson G, Belani C and Lentzsch S: The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol. 139:385–397. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lemoine M and Younes A: Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med. 10:462–470. 2010.PubMed/NCBI
20	Vindeløv LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 3:323–327. 1983. View Article : Google Scholar : PubMed/NCBI
21	Kanayama H, Tanaka K, Aki M, Kagawa S, Miyaji H, Satoh M, Okada F, Sato S, Shimbara N and Ichihara A: Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res. 51:6677–6685. 1991.PubMed/NCBI
22	Liu CY, Takemasa A, Liles WC, Goodman RB, Jonas M, Rosen H, Chi E, Winn RK, Harlan JM and Chuang PI: Broad-spectrum caspase inhibition paradoxically augments cell death in TNF-alpha-stimulated neutrophils. Blood. 101:295–304. 2003. View Article : Google Scholar : PubMed/NCBI